NBC Securities Inc. Grows Position in Novo Nordisk A/S (NYSE:NVO)

NBC Securities Inc. lifted its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 79,440.0% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,954 shares of the company's stock after buying an additional 7,944 shares during the quarter. NBC Securities Inc.'s holdings in Novo Nordisk A/S were worth $552,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of NVO. Center for Financial Planning Inc. lifted its stake in shares of Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after buying an additional 123 shares in the last quarter. Strategic Investment Solutions Inc. IL lifted its stake in shares of Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after buying an additional 300 shares in the last quarter. Park Square Financial Group LLC purchased a new position in shares of Novo Nordisk A/S during the 4th quarter valued at $29,000. Transce3nd LLC purchased a new position in shares of Novo Nordisk A/S during the 4th quarter valued at $33,000. Finally, Kelly Lawrence W & Associates Inc. CA purchased a new position in shares of Novo Nordisk A/S during the 4th quarter valued at $39,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock traded up $0.53 during trading hours on Thursday, reaching $72.57. The company's stock had a trading volume of 5,088,580 shares, compared to its average volume of 6,870,775. The firm has a 50 day moving average price of $65.67 and a 200-day moving average price of $81.09. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The stock has a market cap of $325.64 billion, a P/E ratio of 22.06, a P/E/G ratio of 0.90 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. The firm had revenue of $11.87 billion for the quarter. On average, analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently weighed in on NVO shares. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. Hsbc Global Res upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, April 28th. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Guggenheim downgraded shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Finally, Dbs Bank downgraded shares of Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Two analysts have rated the stock with a sell rating, five have given a hold rating, four have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S has an average rating of "Hold" and a consensus target price of $128.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.